BiomimX: mini-organs for drug testing

14 October 2019
  • Portfolio
  • /

    The startup BiomimX develops functional mini-organs to be used as pre-clinical models to improve drug development and testing.

    The complex journey of drugs

    Before a drug can be marketed, it undergoes a lengthy experimentation process, which can take 10 to 15 years and cost over 1 billion euros.

    This process is divided into several phases, one of which is pre-clinical testing. These tests assess the drug’s efficacy and toxicity in vitro and then in vivo on animals, as required by law.

    These tests are costly both in terms of time and money and do not perfectly predict the drug’s behavior during subsequent human trials.

    Mini-organs: versatile and cost-effective

    For this reason, BiomimX has developed a technology capable of recreating functional human mini-organs in vitro for testing the efficacy and toxicity of new drugs already in the pre-clinical phase.

    This technology is called uBeat, a miniaturized platform consisting of 3D cell cultures with an integrated mechanical stimulation mechanism (organs-on-chips).

    The uBeat platform 1) is versatile because it can be used to recreate various human organs; 2) it increases drug safety by enabling more predictive tests for humans at lower costs; 3) in the future, it could offer an alternative to animal testing.

    Currently, the platform has been used to create uHeart, a model of the human heart, and uKnee, a model of osteoarthritic human joint, but it has the potential to reproduce a wide range of organs with a high level of precision.

    “Mimic human complexity in a beat”

    Paola Ochetta, CEO & Co-founder, BiomimX

    Updates

    April 2022

    💔 BiomimX, in collaboration with the Polytechnic University of Turin, has used uScar, a miniaturized model of cardiac fibrosis developed on the proprietary uBeat® Stretch platforms, to test advanced cardiac reprogramming therapies to counteract the related fibrosis.

    A webinar on the topic will be held on April 27, and registration is available at: https://tinyurl.com/efmde757

    📗 Learn more about BiomimX and other entities in our portfolio.

    BiomimX: mini-organs for drug testing

    14 October 2019
  • Portfolio
  • /

    The startup BiomimX develops functional mini-organs to be used as pre-clinical models to improve drug development and testing.

    The complex journey of drugs

    Before a drug can be marketed, it undergoes a lengthy experimentation process, which can take 10 to 15 years and cost over 1 billion euros.

    This process is divided into several phases, one of which is pre-clinical testing. These tests assess the drug’s efficacy and toxicity in vitro and then in vivo on animals, as required by law.

    These tests are costly both in terms of time and money and do not perfectly predict the drug’s behavior during subsequent human trials.

    Mini-organs: versatile and cost-effective

    For this reason, BiomimX has developed a technology capable of recreating functional human mini-organs in vitro for testing the efficacy and toxicity of new drugs already in the pre-clinical phase.

    This technology is called uBeat, a miniaturized platform consisting of 3D cell cultures with an integrated mechanical stimulation mechanism (organs-on-chips).

    The uBeat platform 1) is versatile because it can be used to recreate various human organs; 2) it increases drug safety by enabling more predictive tests for humans at lower costs; 3) in the future, it could offer an alternative to animal testing.

    Currently, the platform has been used to create uHeart, a model of the human heart, and uKnee, a model of osteoarthritic human joint, but it has the potential to reproduce a wide range of organs with a high level of precision.

    “Mimic human complexity in a beat”

    Paola Ochetta, CEO & Co-founder, BiomimX

    Updates

    April 2022

    💔 BiomimX, in collaboration with the Polytechnic University of Turin, has used uScar, a miniaturized model of cardiac fibrosis developed on the proprietary uBeat® Stretch platforms, to test advanced cardiac reprogramming therapies to counteract the related fibrosis.

    A webinar on the topic will be held on April 27, and registration is available at: https://tinyurl.com/efmde757

    📗 Learn more about BiomimX and other entities in our portfolio.

    BiomimX: mini-organs for drug testing

    14 October 2019
  • Portfolio
  • /

    The startup BiomimX develops functional mini-organs to be used as pre-clinical models to improve drug development and testing.

    The complex journey of drugs

    Before a drug can be marketed, it undergoes a lengthy experimentation process, which can take 10 to 15 years and cost over 1 billion euros.

    This process is divided into several phases, one of which is pre-clinical testing. These tests assess the drug’s efficacy and toxicity in vitro and then in vivo on animals, as required by law.

    These tests are costly both in terms of time and money and do not perfectly predict the drug’s behavior during subsequent human trials.

    Mini-organs: versatile and cost-effective

    For this reason, BiomimX has developed a technology capable of recreating functional human mini-organs in vitro for testing the efficacy and toxicity of new drugs already in the pre-clinical phase.

    This technology is called uBeat, a miniaturized platform consisting of 3D cell cultures with an integrated mechanical stimulation mechanism (organs-on-chips).

    The uBeat platform 1) is versatile because it can be used to recreate various human organs; 2) it increases drug safety by enabling more predictive tests for humans at lower costs; 3) in the future, it could offer an alternative to animal testing.

    Currently, the platform has been used to create uHeart, a model of the human heart, and uKnee, a model of osteoarthritic human joint, but it has the potential to reproduce a wide range of organs with a high level of precision.

    “Mimic human complexity in a beat”

    Paola Ochetta, CEO & Co-founder, BiomimX

    Updates

    April 2022

    💔 BiomimX, in collaboration with the Polytechnic University of Turin, has used uScar, a miniaturized model of cardiac fibrosis developed on the proprietary uBeat® Stretch platforms, to test advanced cardiac reprogramming therapies to counteract the related fibrosis.

    A webinar on the topic will be held on April 27, and registration is available at: https://tinyurl.com/efmde757

    📗 Learn more about BiomimX and other entities in our portfolio.

    BiomimX: mini-organs for drug testing

    14 October 2019
  • Portfolio
  • /

    The startup BiomimX develops functional mini-organs to be used as pre-clinical models to improve drug development and testing.

    The complex journey of drugs

    Before a drug can be marketed, it undergoes a lengthy experimentation process, which can take 10 to 15 years and cost over 1 billion euros.

    This process is divided into several phases, one of which is pre-clinical testing. These tests assess the drug’s efficacy and toxicity in vitro and then in vivo on animals, as required by law.

    These tests are costly both in terms of time and money and do not perfectly predict the drug’s behavior during subsequent human trials.

    Mini-organs: versatile and cost-effective

    For this reason, BiomimX has developed a technology capable of recreating functional human mini-organs in vitro for testing the efficacy and toxicity of new drugs already in the pre-clinical phase.

    This technology is called uBeat, a miniaturized platform consisting of 3D cell cultures with an integrated mechanical stimulation mechanism (organs-on-chips).

    The uBeat platform 1) is versatile because it can be used to recreate various human organs; 2) it increases drug safety by enabling more predictive tests for humans at lower costs; 3) in the future, it could offer an alternative to animal testing.

    Currently, the platform has been used to create uHeart, a model of the human heart, and uKnee, a model of osteoarthritic human joint, but it has the potential to reproduce a wide range of organs with a high level of precision.

    “Mimic human complexity in a beat”

    Paola Ochetta, CEO & Co-founder, BiomimX

    Updates

    April 2022

    💔 BiomimX, in collaboration with the Polytechnic University of Turin, has used uScar, a miniaturized model of cardiac fibrosis developed on the proprietary uBeat® Stretch platforms, to test advanced cardiac reprogramming therapies to counteract the related fibrosis.

    A webinar on the topic will be held on April 27, and registration is available at: https://tinyurl.com/efmde757

    📗 Learn more about BiomimX and other entities in our portfolio.